1
Clinical Trials associated with Volrubigene RalaparvovecVALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Year and Older
This is a Phase 1/2, multinational, open-label, ascending-dose, delayed-treatment concurrent control clinical study to evaluate the safety and preliminary efficacy of AT342 in subjects with Crigler-Najjar aged ≥1 year. Subjects will receive a single dose of AT342 and will be followed for safety and efficacy for 5 years.
100 Clinical Results associated with Volrubigene Ralaparvovec
100 Translational Medicine associated with Volrubigene Ralaparvovec
100 Patents (Medical) associated with Volrubigene Ralaparvovec
100 Deals associated with Volrubigene Ralaparvovec